Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27735913 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPTLMNANPC1 | |
| SCHEMBL20595292 | 0.89 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTLMNANPC1 | |
| SCHEMBL529031 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTLMNANPC1 | |
| SCHEMBL16888113 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPTLMNANPC1 | |
| SCHEMBL4760983 | 0.81 | PTPN1 (0.64) | SMN1; SMN2 | |
| SCHEMBL14273776 | 0.81 | PTPN1 (0.64) | SMN1; SMN2 | |
| SCHEMBL19900281 | 0.81 | ALOX15 (0.56) | ALDH1A1KMT2AMAPTLMNANPC1 | |
| SCHEMBL4716765 | 0.79 | EGFR (0.39) | ALDH1A1MAPTLMNANPC1EGFR | |
| SCHEMBL3221436 | 0.79 | TSHR (0.56) | ALDH1A1LMNAEGFRTSHRHTT | |
| SCHEMBL16377899 | 0.78 | PKM (0.57) | ALDH1A1KMT2AMAPTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101404985-A | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB PUBL (SE) | 2009-04-08 | — | — | CN | disclosed |
| EP-2004159-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | Biovitrum AB (publ) (SE) | 2008-12-24 | — | — | EP | disclosed |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007104790-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | BIOVITRUM AB (PUBL) (SE) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104790-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | BIOVITRUM AB (PUBL) (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | CYBB, NOX1, NOX5 | ALDH1A1 413/4885KMT2A 3330/4885MAPT 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.